Immuneering (IMRX) Enterprise Value (2020 - 2024)
Historic Enterprise Value for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to -$50.7 million.
- Immuneering's Enterprise Value rose 4790.58% to -$50.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$50.7 million, marking a year-over-year increase of 4790.58%. This contributed to the annual value of -$85.7 million for FY2023, which is 1881.94% up from last year.
- Per Immuneering's latest filing, its Enterprise Value stood at -$50.7 million for Q3 2024, which was up 4790.58% from -$59.7 million recorded in Q2 2024.
- Immuneering's Enterprise Value's 5-year high stood at -$37.1 million during Q4 2020, with a 5-year trough of -$149.5 million in Q3 2021.
- Its 5-year average for Enterprise Value is -$96.0 million, with a median of -$97.2 million in 2023.
- In the last 5 years, Immuneering's Enterprise Value plummeted by 30226.14% in 2021 and then surged by 4790.58% in 2024.
- Over the past 5 years, Immuneering's Enterprise Value (Quarter) stood at -$37.1 million in 2020, then tumbled by 302.26% to -$149.2 million in 2021, then grew by 29.27% to -$105.5 million in 2022, then rose by 18.82% to -$85.7 million in 2023, then soared by 40.87% to -$50.7 million in 2024.
- Its last three reported values are -$50.7 million in Q3 2024, -$59.7 million for Q2 2024, and -$71.3 million during Q1 2024.